INTRODUCTION
Population studies have identified the concentration of low density lipoprotein (LDL) cholesterol as a positive predictor of having an atherosclerotic cardiovascular (CV) event (1) . Furthermore, intervention studies have shown that reducing the concentration of LDL cholesterol by treatment with statins decreases the risk of having a CV event (2) . However, even aggressive statin therapy does not eliminate CV risk. One factor that may contribute to residual CV risk in statin-treated patients is a low level of high density lipoprotein (HDL) cholesterol.
Prospective population studies have also identified a low level of HDL cholesterol as an independent predictor of CV risk (1) . This relationship persists even when LDL cholesterol has been decreased to very low levels by treatment with statins (3) . Furthermore, as outlined below, HDLs have several properties that have the potential to protect against the development of atherosclerosis (4) . While there is still no direct evidence from clinical outcome trials in humans that raising the level of HDL cholesterol will translate into a reduction in clinical CV events, there is a large and compelling body of evidence in animal studies (5) (6) ;(7) (8) and growing evidence in human studies (9) (10) , that HDL-raising therapies reduce (6) progression or even promote regression of atheroma. These observations have collectively led to a major research effort to identify therapies with the capacity to raise the concentration of HDL cholesterol as effectively as statins reduce LDL cholesterol levels.
by guest, on www.jlr.org
Downloaded from
One logical therapeutic approach to raising the concentration of HDL cholesterol is to shift the partitioning of cholesterol between LDLs and HDLs in favour of the protective HDL fraction. Given that: (i) most of the cholesterol in human plasma exists in the form of cholesteryl esters, (ii) most of the cholesteryl esters in human plasma originate in HDLs where they are formed in the reaction catalysed by lecithin:cholesterol acyltransferase (LCAT) and (iii) human plasma contains a cholesteryl ester transfer protein (CETP) that promotes the transfer of cholesteryl esters from HDLs to other lipoprotein particles (including LDLs) (11) (12) (13) (14) , it follows that inhibition of CETP has the potential to retain cholesterol in the HDL fraction and thus increase the concentration of HDL cholesterol while decreasing its concentration in potentially atherogenic, non-HDL particles.
BIOLOGICAL EFFECTS OF CETP
CETP is a hydrophobic glycoprotein (15) that is synthesised in several tissues but mainly in the liver (16) . Its crystal structure has been reported and reveals a curved molecule with N-and C-terminal cavities that provide access to cholesteryl esters and triglycerides and a tunnel spanning the entire length of the protein (17) . CETP promotes bidirectional transfers of cholesteryl esters and triglyceride between all plasma lipoprotein particles (12) .
Mechanism of action of CETP
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Two hypotheses have been proposed for the mechanism by which CETP transfers neutral lipids between plasma lipoproteins.
(i) A shuttle mechanism that involves CETP collecting cholesteryl esters from one lipoprotein and delivering them through the aqueous phase to another lipoprotein ( Figure 1 ) (12, 18) (19) .
(ii) A tunnel mechanism in which CETP bridges two lipoproteins to form a ternary complex, with lipids flowing from the donor to acceptor lipoprotein through the CETP molecule ( Figure 2 ) (20) (21) (22) .
Shuttle Mechanism
As shown schematically in Figure 1 , CETP collides randomly with particles in all lipoprotein fractions to form transient lipoprotein-CETP complexes that facilitate exchanges of both cholesteryl esters and triglycerides between lipoprotein particles and CETP. The CETP, and associated neutral lipids, subsequently dissociates from the lipoprotein particles and circulates in a free state until it collides with another lipoprotein particle in either the same (23) or in a different (12) lipoprotein fraction to form a new transient complex that facilitates further exchange of cholesteryl esters and triglyceride between the lipoprotein particle and CETP. In this way, CETP promotes an equilibration of both cholesteryl esters and triglycerides between all lipoprotein particles.
Since most of the cholesteryl esters in plasma are generated in HDLs by the LCAT reaction, while the majority of the triglyceride enters plasma as a Under normal physiological conditions the rate of CETP-mediated cholesteryl ester transfer is rapid relative to the rate of catabolism of HDLs and LDLs (11, 12) such that the pools of cholesteryl esters in HDLs and LDLs are close to complete equilibrium in vivo. This view is supported by the observation that when HDLs and LDLs are incubated in vitro in the presence of CETP there is a high rate of bidirectional transfer of radiolabelled cholesteryl esters, but no net mass transfer in either direction (11). As a consequence of the pools of cholesteryl esters in HDLs and LDLs already being close to equilibrium in vivo, any increase in the activity of CETP beyond physiological levels would be predicted to have little impact on the distribution of cholesteryl esters between these lipoprotein fractions. In contrast, if the activity of CETP were to be inhibited, a point will be reached where CETP activity becomes rate limiting and will impact on the distribution of cholesteryl esters between LDLs and HDLs in vivo.
Tunnel Mechanism
The tunnel mechanism involves the initial formation of a binary complex between an HDL particle and a CETP molecule, with the subsequent formation (following a collision between the binary complex and an LDL or VLDL particle) of a ternary While there is experimental evidence supporting the existence of both the shuttle and tunnel mechanisms, the extent to which either mechanisms operates in vivo remains completely unknown.
Evidence that activity of CETP impacts on plasma lipoprotein concentration, composition and structure
The first evidence that CETP activity impacts on plasma lipoproteins was provided by observations in people with genetic deficiencies of CETP. The first CETP mutation was identified in Japan in 1989 as a cause of markedly elevated HDL-C. Ten mutations associated with CETP deficiency have since been identified in Asians and one in Caucasians. It was found in Japan that 57% of subjects with levels of HDL-C > 100 mg/dL have mutations of the CETP gene. In addition, 37% of Japanese with levels HDL-C between 75-100 mg/dL have mutations of the CETP gene (24) (25) (26) (27) (28) . Similar conclusions were by guest, on www.jlr.org Downloaded from drawn from studies in rabbits that were treated with an anti-CETP antibody that resulted in a substantial increase in the concentration of HDL-C (29) .
Consistent with these observations in CETP deficient patients and rabbits treated with an anti-CETP antibody, it has since been found that treatment of humans with CETP inhibitor drugs (30) (31) (32) (33) increases the concentration of both HDL cholesterol and apoA-I (the major apolipoprotein in HDLs) and in some cases also decreases the concentration of LDL cholesterol and apoB (the main LDL apolipoprotein) over and above the effects achieved by treatment with statins.
In the case of transfers of cholesteryl esters between HDLs and the much more rapidly catabolized TRLs, the amount of CETP in plasma is already rate limiting under most conditions (12) . This is apparent from the net mass transfer of cholesteryl esters from HDLs to TRLs that occurs when the two fractions are incubated in vitro in the presence of CETP (34) . It is therefore not surprising that inhibiting CETP reduces the cholesteryl ester content of TRLs (35) . from macrophages in the artery wall (36) . However, HDLs have several additional potentially anti-atherogenic properties. These include an ability to inhibit oxidation of LDLs (37) , as well as the inhibition of vascular inflammation (38) (39) and thrombosis (40) . HDLs also enhance endothelial function (41), promote both endothelial repair (42) (43) and angiogenesis (44) and improve diabetic control (45) (46) (47).
CETP Inhibition and Atherosclerosis
Relationship between CETP activity and atherosclerosis in animals CETP exists in the plasma of a small number of species, including humans and rabbits but not rodents (14) .
Mice lack CETP and are resistant to the development of atherosclerosis. The results in transgenic mice engineered to express CETP are conflicting and model-dependent. Some of these studies in transgenic mice suggest that CETP is pro-atherogenic (48) (49) (50) while others suggest that it is anti-atherogenic (51) (52) (53) .
In contrast to mice, rabbits have a high level of CETP activity (14) and are extremely susceptible to the development of diet-induced atherosclerosis. 
CETP and atherosclerosis in humans
The relationship of CETP to atherosclerosis in humans is confusing. For example, studies of the relationships between polymorphisms of the CETP gene and human atherosclerotic disease have led in some cases to the conclusion that CETP is pro-atherogenic, while in others it has been concluded that CETP is anti-atherogenic. However, in a large meta-analysis of 92 studies involving 113,833 participants (58), it was concluded that those CETP polymorphisms that are associated with decreased CETP activity and mass have an elevated concentration of HDL cholesterol and a decreased risk of having a coronary event (58) . A similar conclusion was drawn from an analysis of a cohort of 18, 245 healthy American in the Women's Genome Health Study (59) .
In the Honolulu Heart Study 7-year prospective data, there was no statistically significant relation between heterozygous mutations of CETP and either CHD or stroke. However, it was concluded from this and another study that a deficiency of CETP is athero-protective, so long as it is accompanied by an HDL-C level > 60 mg/dL (60, 61) .
Overall, the observations in both animal models and human genetic studies support decisions to test the hypothesis that inhibiting CETP in humans will be by guest, on www.jlr.org
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anti-atherogenic and thus reduce the risk of having an atherosclerotic cardiovascular event.
SMALL MOLECULE CETP INHIBITORS

TORCETRAPIB
Torcetrapib acts by increasing the affinity of CETP for HDLs (62) . This generates a tight complex that reduces the amount of CETP available to promote transfers of cholesteryl esters and triglycerides between different lipoprotein particles. In patients taking effective doses of atorvastatin to reduce the level of LDL-C to below 100 mg/dL, treatment with torcetrapib at a daily dose of 60 mg increased the concentration of HDL cholesterol and apoA-I by 70% and 25%, respectively, and decreased levels of LDL cholesterol and apoB, respectively, by 25% and 12.5% (30) .
Effects of torcetrapib on atherosclerosis in humans
The effect of torcetrapib on atherosclerosis in humans was investigated in three imaging trials. One of these trials (ILLUSTRATE) used intravascular ultrasound (IVUS) to assess the effect of torcetrapib on coronary atheroma burden in patients with demonstrable coronary atheroma (63) , while the other two, cholesterol by approximately 60% in all three of these imaging trials. In addition, the LDL cholesterol level was reduced by approximately 20% over and above that achieved by atorvastatin. Despite this, treatment with torcetrapib had no effect (either positive or negative) on either the atheroma burden in the coronary arteries (63) or on carotid artery intima-media thickness (64, 65) .
Effects of torcetrapib on cardiovascular events
The ILLUMINATE trial (30) However, this possibility will remain unanswered until tested in trials using other CETP inhibitors that do not share the adverse effects of torcetrapib (see below).
(ii) Generation of HDLs that do not function normally. However, as outlined below, there is mounting evidence that this is not the case.
(iii) The observed inverse relationship between the concentration of HDL cholesterol and CV risk in population studies reflects an epiphenomenon rather than a direct anti-atherogenic effect of HDLs. This will remain a possibility until tested in human clinical outcome trials using HDL-raising agents. However, while this could account for the lack of benefit in torcetrapib treated patients, it cannot account for the observed harm related to treatment with the drug. 
Torcetrapib and Functionality of HDL
Currently available evidence does not support the proposition that CETP inhibition compromises the function of HDL particles. In a post-hoc analysis of the group treated with torcetrapib in the ILLUMINATE trial, coronary death and major CV event rates were lower in those where the increase in HDL cholesterol or apolipoprotein A-I was greater than the median compared with those whose increases were below the median level of change (30) . In additional post-hoc analyses of the ILLUMINATE trial, the level of HDL cholesterol achieved in the torcetrapib-treated patients was an inverse predictor of events (66) . However, it must be emphasized that post-hoc observations of this type, while suggesting that the HDLs were apparently functional in torcetrapib-treated patients, do not completely rule out the possibility that the HDLs were dysfunctional or that other unknown adverse effects of CETP inhibition may have contributed to a mechanism-related adverse outcome.
In other studies, HDLs isolated from torcetrapib-treated patients have been investigated in vitro and found to have either a normal or an enhanced ability to promote the efflux of cholesterol from macrophages (67) .
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Additional support for the normal functionality of HDLs in patients treated with torcetrapib has emerged from a post-hoc analysis of the ILLUSTRATE trial that used intravascular ultrasound to assess the effect of torcetrapib on coronary atheromoma burden. In patients treated with torcetrapib in this trial, there was a significant inverse relationship between changes in HDL cholesterol and percentage coronary atheroma volume (68) . Moreover, there was significant regression of coronary atheroma in the group of torcetrapib-treated patients who achieved the highest on-treatment HDL cholesterol levels (68) .
Effects of torcetrapib unrelated to CETP inhibition
Twelve months of treatment with torcetrapib in the ILLUMINATE trial was associated with a 5 mm Hg increase in systolic blood pressure, an increase in serum aldosterone, a reduction in serum potassium and an increase in serum concentrations of bicarbonate and sodium (30) . The possibility that an increase in aldosterone secretion may have contributed to the clinical harm caused by torcetrapib was supported by the observation of a higher coronary heart disease (CHD) mortality in those whose reduction in serum potassium or increase in bicarbonate (30) was greater than the median. (69) (31), have no effect on blood pressure or serum aldosterone levels in either animals or humans. Nor do they induce synthesis of aldosterone in studies of adrenal cortical cells (69) . In a subsequent study investigating the effects of CETP polymorphisms on blood pressure, it was concluded that the hypertensive effects of torcetrapib were unlikely to be due to CETP inhibition, or to be shared by chemically dissimilar CETP inhibitors (72) . Torcetrapib also impairs endothelial function in a process that is independent of either CETP inhibition or changes in HDL cholesterol levels (73) (74). However, while consistent with a proposition that off-target effects of torcetrapib were responsible for the harm observed in the ILLUMINATE trial and the absence of an effect on atherosclerosis in the imaging trials, these post-hoc and preclinical studies cannot be regarded as definitive.
Effects of torcetrapib on diabetic control
One unexpected beneficial effect of torcetrapib observed in a post-hoc analysis of the ILLUMINATE data was evidence of a significant improvement in diabetic control in patients with diabetes ( Figure 5 assessment of insulin resistance (HOMA-IR). After three months of treatment, the diabetic subjects taking the combination of torcetrapib plus atorvastatin had plasma glucose levels 0·34 mmol/L lower (p<0·0001) and insulin levels 11·7 mU/mL lower (p<0·0001) than those receiving atorvastatin alone (75) . HOMA-IR values decreased from 49·1 to 47·3 (p<0·0001) in those taking torcetrapib plus atorvastatin compared with an increase in HOMA-IR in those taking atorvastatin alone ( Figure 5 ). After six-months of treatment HbA1C levels were significantly lower in those taking torcetrapib (7.06%) compared to those in the control arm (7.29%) (p<0·0001). These effects of torcetrapib remained apparent for up to 12 months. Torcetrapib also lowered both glucose and insulin levels in the participants without diabetes, although the effects were not as great as in those with diabetes. However, it remains to be determined from the results in trials with other CETP inhibitors whether this effect of torcetrapib was the consequence of CETP inhibition, whether it was due to HDL-raising or whether it could be attributed to a (beneficial) off-target effect of torcetrapib unrelated to either a reduction in CETP activity or increased HDL levels.
FUTURE OF CETP INHIBITION AFTER THE FAILURE OF TORCETRAPIB
The post-hoc analyses of the ILLUMINATE and ILLUSTRATE trials, combined with the preclinical data demonstrating adverse off-target effects of torcetrapib unrelated to CETP inhibition, have provided the basis for re-examining the hypothesis that inhibition of CETP will be anti-atherogenic. The hypothesis is currently being tested in large clinical outcome trials with two CETP inhibitors, 
DALCETRAPIB
The first reported small molecule CETP inhibitor, dalcetrapib (previously known as JTT-705), inhibited atherosclerosis in cholesterol-fed rabbits (56) and paved the way for testing the hypothesis that inhibiting CETP in humans may be atheroprotective.
The first human study of CETP inhibition was conducted with dalcetrapib at daily doses of 300, 600 and 900 mg (32) . Dalcetrapib was well tolerated and promoted
dose-dependent increases in HDL cholesterol and decreases in LDL-C (32).
After 4 weeks of therapy, the 900 mg dose reduced CETP activity by 37%. This was associated with a 34% increase in HDL cholesterol and a 7% reduction in LDL cholesterol. In a subsequent study, dalcetrapib (600 mg per day) given in combination with pravastatin decreased CETP activity by 30% and increased HDL cholesterol by 28% but had little effect on the level of LDL cholesterol relative to those treated with paravastatin alone (76).
The precise mechanism by which dalcetrapib inhibits CETP activity is still uncertain, although it has been suggested that it is the consequence of a conformational change in CETP that decreases the transfer of cholesteryl esters from HDLs to other lipoprotein fractions while having no effect on the ability of In contrast to torcetrapib, dalcetrapib does not increase blood pressure or reninangiotensin-aldosterone-related gene expression, providing further evidence that some of the known off-target effects of torcetrapib are not a common feature of all compounds that inhibit CETP. The effects of dalcetrapib and torcetrapib on aldosterone synthesis have also been compared in tissue culture in a human adrenocarcinoma cell line (71) (78) . Again, in contrast to torcetrapib, dalcetrapib had no effect on either aldosterone synthase or aldosterone production in these cells.
Effects of dalcetrapib on atherosclerotic plaques in humans
The dal-PLAQUE trial was a multicentre study that used non-invasive multimodality imaging to assess the effect of dalcetrapib on atherosclerosis (79).
Patients (aged 18-75 years) with manifest CHD or at high risk of having a coronary event were randomly assigned to receive dalcetrapib 600 mg/day or matching placebo for 24 months. Endpoints included: (i) total vessel area, wall area, wall thickness and the normalized carotid artery wall index as assessed by A total of 130 participants were randomly assigned to placebo (n=66) or dalcetrapib (n=64). Of the 5 primary endpoints, all were negative with the exception of the MRI-derived change in total vessel area that was significantly reduced by dalcetrapib compared with placebo. While there was no difference between groups in the PET/CT measure of the most-diseased-segment, an analysis limited to the carotid artery revealed a significant 7% reduction in the most-diseased-segment. Overall, however, it has to be concluded that the effects on most of the primary outcome measures were disappointing. In terms of safety, dalcetrapib had no effect on blood pressure and the frequency of adverse events was similar in the two groups, although conclusions regarding safety are limited by the very small sample size (79).
Effects of dalcetrapib on endothelial function in humans
In a study of patients with hypercholesterolemia, dalcetrapib improved endothelial function in a subgroup of patients whose HDL cholesterol level was low at baseline but had no effect in those with higher baseline HDL levels (80) . (81) . Dalcetrapib had no effect on LDL-C levels. When compared with the placebo group, dalcetrapib had no effect on FMD after either 12 or 36 weeks of treatment. In terms of safety, dalcetrapib had no effect on ambulatory blood pressure up to 36 weeks of treatment. Biomarkers of inflammation, oxidative stress and coagulation were unaffected by dalcetrapib up to 36 weeks, although Lp-PLA2 levels were increased by 17% in those taking dalcetrapib.
The major conclusion to be drawn from the dal-VESSEL trial is that there was no evidence that dalcetrapib improved endothelial function (81) .
Effects of dalcetrapib on clinical cardiovascular outcomes in humans
Dal-OUTCOMES (ClinicalTrials.gov Identifier: NCT00658515) was a phase III, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to test the hypothesis that CETP inhibition with dalcetrapib reduces cardiovascular morbidity and mortality in patients with recent acute coronary syndromes (ACS) (82) . More than 15,000 patients, all of whom were treated with by guest, on www.jlr.org Downloaded from statins to achieve recommended levels of LDL cholesterol, were randomised to receive dalcetrapib at a daily dose of 600 mg or matching placebo. The primary outcome was time to first occurrence of a composite cardiovascular endpoint that included CHD death, nonfatal acute myocardial infarction, unstable angina requiring hospital admission, resuscitated cardiac arrest or athero-thrombotic stroke). The trial was planned to continue until 1,600 primary end point events have occurred with an anticipated reporting in 2013.
However, it was announced in early May 2012 that the trial had been terminated on the basis of futility (Roche provides update on Phase III study of dalcetrapib.
Roche press release, May 7, 2012;  (http://www.roche.com/media/media_releases/med-cor-2012-05-07.htm).
The decision to terminate the trial was based on the second interim analysis by the Data and Safety Monitoring Committee, who concluded that further continuation of the study had virtually no chance of yielding a positive result. As a consequence, the decision was made to stop the dal-OUTCOMES trial and to terminate the entire dalcetrapib development program.
It is important to stress that the dal-OUTCOMES trial was not terminated on the basis of safety. As was found in the extensive phase 2 program with dalcetrapib, there was no evidence that dalcetrapib shared any of the off-target adverse effects observed with torcetrapib. 
ANACETRAPIB
When given at a daily dose of 100 mg, anacetrapib more than doubles the concentration of HDL cholesterol and reduces LDL cholesterol levels by as much as 40% (over and above the reduction achieved with a statin) (31) . It has no effect on blood pressure, aldosterone or serum electrolytes in humans (31) and does not stimulate the synthesis of aldosterone in adrenal cortical cells growing in tissue culture (69) . Furthermore, HDLs isolated from people taking anacetrapib have a normal or enhanced functionality, as assessed by their ability ex vivo to promote efflux of cholesterol from macrophages (67) . In studies conducted in a dyslipidemic hamster model it has been shown that, like dalcetrapib, anacetrapib enhances macrophage-to-feces reverse cholesterol transport as evidenced by an increased fecal excretion of both cholesterol and bile acids (84) . The precise mechanism by which anacetrapib inhibits CETP is not known, although, like torcetrapib, it promotes a tight binding of CETP to HDL particles (85) . This immobilises CETP, making it unavailable to shuttle cholesteryl esters between lipoprotein particles. Anacetrapib, torcetrapib and dalcetrapib compete with one another for binding CETP (85) , although it remains uncertain how this relates to the mechanism of action of any of these agents.
Safety of anacetrapib in humans
The DEFINE study was a randomized, double-blind, placebo-controlled 18 month trial designed to assess the lipid efficacy and safety profile of anacetrapib in patients (n=1623) with manifest or at high risk of developing CHD. All participants were taking a statin to achieve optimal levels of LDL cholesterol before being randomised to receive anacetrapib 1(00 mg per day) or matching placebo (31) .
By 24 weeks, the LDL cholesterol level had been reduced from 81 mg/dL to 45 mg/dL in the anacetrapib group, as compared with a reduction from 82 mg/dL to 77 mg/dL in the placebo group, a 40% reduction with anacetrapib beyond that seen with placebo. The HDL cholesterol level increased from 41 mg/dL at baseline to 101 mg/dL in the anacetrapib group, as compared with an increase from 40 mg/dL to 46 mg/dL in the placebo group, an increase of 138% with anacetrapib beyond that seen with placebo. Treatment with anacetrapib had no effect on blood pressure or on electrolyte or aldosterone levels. Pre-specified adjudicated CV events occurred in 16 patients treated with anacetrapib (2.0%) by guest, on www.jlr.org Downloaded from and 21 patients receiving placebo (2.6%) (P = 0.40). The pre-specified Bayesian analysis indicated that this event distribution provided a predictive probability of 94% that anacetrapib would not be associated with the increase in CV events seen with torcetrapib. Significantly fewer patients in the anacetrapib group than in the placebo group underwent revascularization (8 vs. 28, P = 0.001) (31) . It was concluded that treatment with anacetrapib had robust favourable effects on levels of LDL cholesterol and HDL cholesterol, had an acceptable side-effect profile, and, within the limits of the power of this study, did not result in the adverse cardiovascular effects observed with torcetrapib. A comparison of the cardiovascular end points in the DEFINE and ILLUMINATE studies is shown in Figure 6 . effects of evecetrapib were observed in this study (33) . There is no indication to date that a planned large phase 3 clinical outcome study using evacetrapib will be reconsidered in the light of the results of the dal-OUTCOMES trial.
BAY 60-5521
BAY 60-5521 is another CETP inhibitor in early development, but to date there is relatively little information of its effects in humans. The early results suggest that the agent is clinically safe and well tolerated, with no effects on heart rate or blood pressure (87) Further results are awaited with interest.
CONTROVERSIES AND UNANSWERED QUESTIONS RELATED TO CETP
INHIBITION
There are three main areas of controversy related to the use of CETP inhibitors as agents to reduce cardiovascular risk.
by guest, on www.jlr.org Downloaded from (i) The first (and most fundamental) relates to suggestions that are frequently made that inhibition of CETP will be pro-atherogenic rather than anti-atherogenic.
It should be noted, however, that such assertions are not based on hard evidence and cannot be answered by the results of currently available studies.
Indeed, the issue of whether CETP inhibition is anti-or pro-atherogenic will remain unanswered until the results of ongoing clinical outcome trials are known.
(ii) A second controversy relates to the effect of CETP inhibition on HDL function.
Again it is often asserted (with no supporting evidence) that inhibition of CETP generates dysfunctional HDL particles. However, this view is not consistent with the observation that HDLs isolated from patients treated with anacetrapib have, if anything, an enhanced ability to promote the efflux of cholesterol from macrphages (88).
(iii) The third area of controversy relates to suggestions that dalcetrapib and anacetrapib inhibit CETP by different mechanisms. While it was suggested that the difference in mechanism may translate into dalcetrapib having superior antiatherogenic properties to those of anacetrapib, the results of the dal-OUTCOMES trial clearly negate such a proposition. However, it remains to be seen whether anacetrapib (or evacetrapib) is any more effective in reducing cardiovascular risk than dalcetrapib. 
